Otonomy

Otonomy Equity

Delisted

The The Equity of Otonomy (OTIC) as of Nov 9, 2026 is 54.91 M USD. In the previous year, The Equity was 66.30 M USD — a change of -17.18% (lower).

Equity

54.91 MUSD

YoY

-17.18%

Last updated:

In 2021, Otonomy's equity was 54.91 M USD, a -17.18% increase from the 66.30 M USD equity in the previous year.

The Otonomy Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2014
153.60 M USD
Jan 1, 2015
181.50 M USD
Jan 1, 2016
192.70 M USD
Jan 1, 2017
117.30 M USD
Jan 1, 2018
79.70 M USD
Jan 1, 2019
40.20 M USD
Jan 1, 2020
66.30 M USD
Jan 1, 2021
54.91 M USD
The Otonomy Equity history
YEAREquityYoY
54.91 MUSD-17.18%
66.30 MUSD+64.93%
40.20 MUSD-49.56%
79.70 MUSD-32.05%
117.30 MUSD-39.13%
192.70 MUSD+6.17%
181.50 MUSD+18.16%
153.60 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Otonomy Stock analysis

What does Otonomy do? Otonomy Inc is a biopharmaceutical company focused on developing innovative therapies for inner ear disorders. The company was founded in 2008 in San Diego, California and has since made significant advancements to bring its products to market. Otonomy's business model is based on identifying unmet medical needs in the field of otolaryngology. The company develops and markets FDA-approved ear medications that are designed in new and innovative ways to improve the treatment of hearing and balance disorders. The different divisions of Otonomy include clinical research, product development, manufacturing, and distribution. The company has an experienced team of scientists, engineers, clinical researchers, and managers who work closely together to develop and bring Otonomy's pipeline of drug candidates to market. The company has launched a number of products targeting the needs of patients with inner ear disorders. For example, the medication Otiprio was developed to treat otitis media, an inflammation of the middle ear. Otiprio is delivered directly into the ear during a minor surgery, where it quickly acts to eliminate the inflammation. Another one of Otonomy's products is Otividex, a medication developed to treat patients with Meniere's disease. This condition is a rare inner ear disorder that causes dizziness, tinnitus, and hearing loss. Otividex is also delivered directly into the ear and has shown to alleviate the dizziness symptoms and improve hearing. In recent years, Otonomy has also developed a new technology called OTO-413, which aims to improve hearing by regenerating damaged hair cells in the inner ear. The company has successfully conducted clinical trials with OTO-413 and plans to further explore and develop the technology. Otonomy has also formed partnerships with other companies and organizations in recent years to further develop its technologies and bring new products to market. For example, the company has entered into a collaboration agreement with Merck to develop new therapies for inner ear disorders. Otonomy also collaborates with a number of academic institutions and research facilities to further explore and develop the potential of its technologies. Overall, Otonomy Inc is an innovative and dynamic company dedicated to developing new therapies for inner ear disorders. With a strong pipeline of drug candidates and a dedicated group of scientists and researchers, the company is well positioned to make significant advancements in the treatment of hearing and balance disorders in the coming years. Otonomy is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Otonomy's Equity

Otonomy's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Otonomy's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Otonomy's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Otonomy's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Otonomy’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Otonomy stock

The Equity of Otonomy is 54.91 M USD in 2021.

The Equity of Otonomy changed from 66.30 M USD to 54.91 M USD, representing a -17.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Otonomy since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Otonomy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Otonomy

All Key Metrics — Otonomy